The main issues with MESO revolve around productio

The main issues with MESO revolve around production, delivery, and administration of the treatment... given the other indications for Leronlimab and timeline with CYDY, I've passed on most of the other "trades" for CV. Many will still have significant, news-driven pops, a few might reach the finish line after several months, but Cytodyn stands out even in the CV testing, treatment, and "vaccine" space... this is the best shot at being the linchpin that begins to restore some real semblance of normalcy. That platform may come to fruition on a number of fronts / indications as well, just don't see that for quite some time still... JMO my capital would be better off invested here in the meantime, YMMV.